ChAdOx

A ChAdOx-platform Bundibugyo ebolavirus vaccine candidate is two to three months from being ready for human trial doses as of May 2026, though it has not yet accumulated the human safety data required for use in an active outbreak. The vaccine lacks regulatory clearance and trial approval; its timeline runs parallel to, but does not affect, the WHO-sponsored therapeutic trial of remdesivir and MBP134.

ChAdOx (chimpanzee adenovirus Oxford) is a viral-vector vaccine platform developed at the Jenner Institute, University of Oxford. It uses a modified, replication-deficient chimpanzee adenovirus to deliver genetic instructions for a target pathogen's antigen into human cells, triggering an immune response. The platform gained global recognition as the basis of the Oxford/AstraZeneca COVID-19 vaccine (AZD1222), which was deployed at enormous scale from late 2020 and was the primary vaccine used across much of the developing world in 2021. The Oxford group subsequently adapted ChAdOx toward vaccine candidates for Ebola, Middle East Respiratory Syndrome (MERS), and other high-priority pathogens.

ChAdOx's key advantage is its established manufacturing infrastructure and its documented safety profile from COVID-19 deployment in hundreds of millions of people, which accelerates regulatory review for new candidates on the same platform. For Bundibugyo specifically, ChAdOx offers a faster route to trial than entirely novel platforms, though it remains further from deployment than the therapeutic options in the current WHO trial. If human safety data for the Bundibugyo ChAdOx candidate accrues during the current outbreak window, it would position the platform as a primary candidate for a future ring-vaccination strategy.